Literature DB >> 2162905

Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity.

G Scala1, I Quinto, M R Ruocco, A Arcucci, M Mallardo, P Caretto, G Forni, S Venuta.   

Abstract

The biological role of interleukin 6 (IL-6) molecules in human B cell tumorigenesis was studied by using an episomal expression vector, pHEBoSV-IL6, to introduce stably the human IL-6 gene into human Epstein Barr virus (EBV)-transformed B lymphoblasts. The gene was present in the IL-6-transfected cells in a high copy number and was efficiently expressed, resulting in the secretion of consistent levels of IL-6 molecules. The constitutive expression of the IL-6 gene led to an altered pattern of growth and to a malignant phenotype, as shown by clonogenicity in to an altered pattern of growth and to a malignant phenotype, as shown by clonogenicity in soft agar cultures and tumorigenicity in nude mice. These data suggest that the combined action of EBV, which exerts an immortalizing function, and of the growth-promoting activity of IL-6 molecules, can give rise to fully transformed B cell tumors in immunodeficient subjects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162905      PMCID: PMC2188154          DOI: 10.1084/jem.172.1.61

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  21 in total

1.  Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6).

Authors:  G Tosato; K B Seamon; N D Goldman; P B Sehgal; L T May; G C Washington; K D Jones; S E Pike
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

Review 2.  The biology of interleukin-6.

Authors:  T Kishimoto
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

3.  Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts.

Authors:  L Lombardi; E W Newcomb; R Dalla-Favera
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

4.  Anti-beta-interferon antibodies inhibit the increased expression of HLA-B7 mRNA in tumor necrosis factor-treated human fibroblasts: structural studies of the beta 2 interferon involved.

Authors:  L T May; D C Helfgott; P B Sehgal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

5.  The role of interferon-beta 1 and the 26-kDa protein (interferon-beta 2) as mediators of the antiviral effect of interleukin 1 and tumor necrosis factor.

Authors:  J Van Damme; M De Ley; J Van Snick; C A Dinarello; A Billiau
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

6.  A new childhood T-cell lymphoma established in nude mice and in vitro.

Authors:  R Arione; C Jemma; M Forni; C Marchese; G Benetton; C Giubellino; A Modesti; M G Martinotti; L C di Montezemolo; T Musso
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

7.  Autocrine growth function of human interleukin 1 molecules on ROHA-9, an EBV-transformed human B cell line.

Authors:  G Scala; G Morrone; M Tamburrini; F Alfinito; C I Pastore; G D'Alessio; S Venuta
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

8.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

Authors:  J Van Snick; S Cayphas; A Vink; C Uyttenhove; P G Coulie; M R Rubira; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.

Authors:  A Muraguchi; T Hirano; B Tang; T Matsuda; Y Horii; K Nakajima; T Kishimoto
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

10.  Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor.

Authors:  J Van Damme; G Opdenakker; R J Simpson; M R Rubira; S Cayphas; A Vink; A Billiau; J Van Snick
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more
  20 in total

1.  Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.

Authors:  J Tanner; G Tosato
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 2.  Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.

Authors:  Shannon Kenney
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

3.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

Review 4.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.

Authors:  Gregory K Hong; Margaret L Gulley; Wen-Hai Feng; Henri-Jacques Delecluse; Elizabeth Holley-Guthrie; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells.

Authors:  Sophia Spadavecchia; Olga Gonzalez-Lopez; Kyla Driscoll Carroll; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

7.  Polymorphisms in immune function genes and non-Hodgkin lymphoma survival.

Authors:  Briseis Aschebrook-Kilfoy; Tongzhang Zheng; Francine Foss; Shuangge Ma; Xuesong Han; Qing Lan; Theodore Holford; Yingtai Chen; Brian Leaderer; Nathaniel Rothman; Yawei Zhang
Journal:  J Cancer Surviv       Date:  2011-11-24       Impact factor: 4.442

Review 8.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998

9.  Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies.

Authors:  A Durandy; N Brousse; F Rozenberg; G De Saint Basile; A M Fischer; A Fischer
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.

Authors:  G Scala; I Quinto; M R Ruocco; M Mallardo; C Ambrosino; B Squitieri; P Tassone; S Venuta
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.